Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
In an interview with The Canadian Press in late December, Novo Nordisk Canada president Vince Lamanna declined to give any details about the patent lapse, citing intellectual property confidentiality
Primary endpoints focused on safety and tolerability, including adverse event monitoring, vital signs, laboratory parameters, and electrocardiographic assessments
The consistent superiority of Tirzepatide over a best-in-class active comparator signaled a paradigm shift in incretin-based therapy and provided strong evidence for the added benefit of GIP receptor agonism
Lee MMY, et al
US$ 26.47
US$ 24.19
US$ 29.67
US$ 22.38
US$ 27.69
US$ 26.65
US$ 24.92
US$ 28.90
US$ 27.23
US$ 26.82
US$ 20.37
